Heart Failure Clinical Trials in Los Angeles, California

17 studies are recruiting for heart failure in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Alleviant ALLAY-HFrEF Study

   Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFrEF.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Keck Medical Center of USC, Los Angeles, California

   Locations

   68 in total

   Run by

   Alleviant Medical, Inc.

   See if you can join NCT06812533 on ClinicalTrials.gov

2. Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

   Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin…

   Stage

   Phase 3

   Ages

   40 and older

   Site

   Research Site, Los Angeles, California

   Locations

   957 in total

   Run by

   AstraZeneca

   See if you can join NCT06677060 on ClinicalTrials.gov

3. A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

   Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Los Angeles, CA Investigative Site 10089, Los Angeles, California

   Locations

   356 in total

   Run by

   Colorado Prevention Center

   See if you can join NCT06008197 on ClinicalTrials.gov

4. Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

   The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

   Stage

   Not phased

   Ages

   18 to 100

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Locations

   47 in total

   Run by

   BrioHealth Solutions, Inc.

   See if you can join NCT06310031 on ClinicalTrials.gov

5. Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

   This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.

   Stage

   Phase 2

   Ages

   0 to 17

   Site

   The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 0002), Los Angeles, California

   Locations

   109 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT05714085 on ClinicalTrials.gov

6. Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

   The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

   Stage

   Phase 3

   Ages

   18 to 85

   Site

   Keck Medical Center of USC (outpatient clinic), Los Angeles, California

   Locations

   205 in total

   Run by

   Cytokinetics

   See if you can join NCT06736574 on ClinicalTrials.gov

7. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

   The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK…

   Stage

   Not phased

   Ages

   0 to 20

   Site

   University of California, Los Angeles Medical Center, Los Angeles, California

   Locations

   52 in total

   Run by

   Duke University

   See if you can join NCT04278404 on ClinicalTrials.gov

8. Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

   The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

   Stage

   Not phased

   Ages

   Any age

   Site

   Research site, Los Angeles, California

   Locations

   333 in total

   Run by

   Medtronic

   See if you can join NCT00271180 on ClinicalTrials.gov

9. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

   This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   VAGrtrLosAngelesHlthcareSystem, Los Angeles, California

   Locations

   838 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07567001 on ClinicalTrials.gov

10. Assessment of CCM in HF With Higher Ejection Fraction

    The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

    Stage

    Not phased

    Ages

    18 and older

    Site

    USC Keck School of Medicine, Los Angeles, California

    Locations

    105 in total

    Run by

    Impulse Dynamics

    See if you can join NCT05064709 on ClinicalTrials.gov

11. Staged Kidney Transplantation During Combined Heart/Kidney Transplantation

    The primary purpose of this study is to evaluate the safety and efficacy of ex vivo machine perfusion with staged implantation of kidney allografts during combined heart/kidney transplantation.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Cedars-Sinai Medical Center, Los Angeles, California

    Run by

    Cedars-Sinai Medical Center

    See if you can join NCT06877169 on ClinicalTrials.gov

12. The STOP-MED CTRCD Trial

    Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart f…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    University of California, Los Angeles, Los Angeles, California

    Locations

    14 in total

    Run by

    Dinesh Thavendiranathan

    See if you can join NCT06183437 on ClinicalTrials.gov

13. PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

    This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate saf…

    Stage

    Not phased

    Ages

    18 and older

    Site

    USC, Los Angeles, California

    Locations

    48 in total

    Run by

    Endotronix, Inc.

    See if you can join NCT05934487 on ClinicalTrials.gov

14. The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

    The objective of this prospective, randomized, double- blinded (patient and assessors), sham-controlled clinical trial is to assess the safety and efficacy of the CMCS in treating heart failure with functional regurgitation (FMR).

    Stage

    Not phased

    Ages

    18 and older

    Site

    Keck School of Medicine of USC, Los Angeles, California

    Locations

    92 in total

    Run by

    Cardiac Dimensions, Inc.

    See if you can join NCT03142152 on ClinicalTrials.gov

15. XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

    The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Cedars Sinai Medical Center, Los Angeles, California

    Locations

    14 in total

    Run by

    XVIVO Perfusion

    See if you can join NCT06895070 on ClinicalTrials.gov

16. His-Bundle Corrective Pacing in Heart Failure

    The investigators aim to prospectively evaluate the efficacy and mechanism of benefit of His-bundle pacing enhanced cardiac resynchronization therapy (His-CRT) vs. cardiac resynchronization therapy (BIV-CRT) in patients with heart failure and right bundle branch block (RBBB).

    Stage

    Not phased

    Ages

    18 and older

    Site

    Cedars-Sinai Medical Center, Los Angeles, California

    Locations

    14 in total

    Run by

    University of Rochester

    See if you can join NCT05265520 on ClinicalTrials.gov

17. Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients

    This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).

    Stage

    Phase 2

    Ages

    18 to 90

    Site

    Cedars-Sinai Medical Center, Los Angeles, California

    Locations

    3 in total

    Run by

    Baylor Research Institute

    See if you can join NCT03383419 on ClinicalTrials.gov